2023-06-10 22:00:00
LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a company specializing in the development of therapeutic peptides targeting rare endocrine and metabolic diseases, announced today that it is hosting an event with leaders on eneboparatide, its lead investigational drug candidate for the treatment of hypoparathyroidism. It will be held on Friday, June 16, 2023 at 8:30 AM CT (9:30 AM ET) at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois, USA. The event will also be broadcast on the internet for people who cannot attend in person.
Aliya Khan, M.D., FRCPC, FACP, FACE, FASBMR (McMaster University Medical Centre) will address the unmet medical needs of patients with hypoparathyroidism and present comprehensive results from the Phase 2a trial of eneboparatide, a parathyroid hormone receptor 1 (PTHR1) agonist with a novel mechanism of action.
Patty Keatingpatient and president of the HypoPARAthyroidism association, will share her personal experience of the disease and the challenges posed by the current reference treatment.
Mark Sumeray, M.D., Medical Director of Amolyt Pharma, will provide an update on the Calypso study, the Phase 3 clinical trial of eneboparatide for the treatment of patients with hypoparathyroidism.
The presentations will be followed by a live Q&A session. To register for the event, click ici.
About hypoparathyroidism
Hypoparathyroidism is characterized by a deficiency in parathyroid hormone (PTH) which causes hypocalcemia and high levels of phosphorus in the blood. Approximately 80,000 people in the United States and 110,000 in Europe suffer from hypoparathyroidism, 80% of whom are women. Despite available treatments, patients suffer from persistent and severe symptoms. They often develop complications and comorbidities that affect their quality of life, and thus represent population segments with specific clinical needs. Clinical manifestations vary and may involve many tissues and organs, especially the kidneys and bones.
17% of patients with hypoparathyroidism suffer from osteopenia or osteoporosis and 53% are peri- or post-menopausal women who are at risk of developing osteoporosis. It is also estimated that 26% of patients with hypoparathyroidism have chronic kidney disease or renal failure, supporting the therapeutic need to reduce urinary calcium excretion.
About eneboparatide
Eneboparatide is an investigational peptide therapeutic that acts selectively on a specific conformation of the parathyroid hormone (PTH) receptor to induce a prolonged effect on calcium metabolism and thereby control the symptoms of hypoparathyroidism. Its action might also limit the urinary excretion of calcium by restoring calcium reabsorption by the kidney, with the aim of preventing chronic kidney disease. In addition, eneboparatide’s unique mode of action and short half-life should preserve bone integrity, a major potential benefit considering that the majority of patients with hypoparathyroidism are peri- or post-operative women. -menopausal, often at risk of osteoporosis.
About Amolyt Pharma
Amolyt Pharma, a clinical-stage biotechnology company, relies on the know-how and experience of its team to develop treatments aimed at improving the lives of patients suffering from rare endocrine diseases. Its development pipeline includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a growth hormone receptor antagonist for the treatment potential for acromegaly. Amolyt Pharma intends to continue building its product portfolio by relying on its global network in the field of endocrinology, and with the support of its syndicate of international investors. To find out more, visit https://amolytpharma.com/ or follow us on Twitter @AmolytPharma and on LinkedIn.
Media relations:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor relations:
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
+1.617.430.7577
1686455214
#Amolyt #Pharma #Hosting #Hybrid #KOL #Event #June #Chicago #Eneboparatide #PTHR1 #Agonist #Entering #Phase #Treatment #Hypoparathyroidism
